Daily Stock Analysis, GLYC, GlycoMimetics Inc, priceseries

GlycoMimetics Inc. Daily Stock Analysis
Stock Information
Open
2.91
Close
3.05
High
3.09
Low
2.75
Previous Close
2.91
Daily Price Gain
0.14
YTD High
13.56
YTD High Date
Mar 27, 2019
YTD Low
2.64
YTD Low Date
Aug 5, 2019
YTD Price Change
-6.97
YTD Gain
-69.56%
52 Week High
16.35
52 Week High Date
Aug 21, 2018
52 Week Low
2.64
52 Week Low Date
Aug 5, 2019
52 Week Price Change
-11.29
52 Week Gain
-78.73%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 12. 2017
5.00
Jun 5. 2017
11.16
15 Trading Days
123.12%
Link
LONG
Sep 15. 2017
11.82
Oct 2. 2017
13.42
11 Trading Days
13.53%
Link
LONG
Dec 21. 2017
16.14
Jan 16. 2018
18.59
15 Trading Days
15.20%
Link
LONG
Jan 17. 2018
19.65
Feb 1. 2018
22.36
11 Trading Days
13.77%
Link
LONG
Dec 31. 2018
9.47
Jan 14. 2019
10.41
9 Trading Days
9.94%
Link
Company Information
Stock Symbol
GLYC
Exchange
NasdaqGM
Company URL
http://www.glycomimetics.com
Company Phone
240-243-1201
CEO
Rachel K. King
Headquarters
Maryland
Business Address
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD 20850
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001253689
About

GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani in April 2003 and is headquartered in Rockville, MD.

Description

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.